title: Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia.
abstract: Despite being considered "good-risk" acute myelogenous leukemia (AML), long term outcomes in core binding factor (CBF) AML suggest room for improvement. We report on a regimen consisting of fludarabine, cytarabine, granulocyte colony stimulating factor, and low dose gemtuzumab ozogamicin (FLAG-GO) as front-line therapy of patients with CBF AML. Forty-five patients were enrolled (median age 48 years). Remission rate was 95% with 5% induction deaths. The overall survival (OS) and relapse free survival (RFS) probability at 3 years are 78% and 85%, respectively. FLAG-GO regimen results in high rates of RFS and OS in CBF AML. Our data along with recent data from several large groups strongly argues in favor of incorporation of gemtuzumab ozogamicin in frontline regimens for CBF AML.
authors.affiliation: Department of Leukemia, MD Anderson Cancer Center, Houston, Texas.
authors.forename: Gautam
authors.initials: G
authors.lastname: Borthakur
authors.forename: Jorge E
authors.initials: JE
authors.lastname: Cortes
authors.forename: Elihu E
authors.initials: EE
authors.lastname: Estey
authors.forename: Elias
authors.initials: E
authors.lastname: Jabbour
authors.forename: Stefan
authors.initials: S
authors.lastname: Faderl
authors.forename: Susan
authors.initials: S
authors.lastname: O'Brien
authors.forename: Guillermo
authors.initials: G
authors.lastname: Garcia-Manero
authors.forename: Tapan Mahendra
authors.initials: TM
authors.lastname: Kadia
authors.forename: Xuemei
authors.initials: X
authors.lastname: Wang
authors.forename: Keyur
authors.initials: K
authors.lastname: Patel
authors.forename: Rajyalakshmi
authors.initials: R
authors.lastname: Luthra
authors.forename: Charles
authors.initials: C
authors.lastname: Koller
authors.forename: Mark
authors.initials: M
authors.lastname: Brandt
authors.forename: Farhad
authors.initials: F
authors.lastname: Ravandi
authors.forename: Hagop
authors.initials: H
authors.lastname: Kantarjian
mesh_terms: D000328:Adult; D000368:Aged; D000617:Aminoglycosides / Q000008:administration & dosage / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D050660:Core Binding Factors; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects; D018572:Disease-Free Survival; D005260:Female; D000079982:Gemtuzumab; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality; D008297:Male; D008875:Middle Aged; D015996:Survival Rate; D014740:Vidarabine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives
chemical_list: D000617:Aminoglycosides; D061067:Antibodies, Monoclonal, Humanized; D050660:Core Binding Factors; D003561:Cytarabine; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D000079982:Gemtuzumab; D014740:Vidarabine; C024352:fludarabine